Oncology Account Manager

Diaceutics accelerates growth on precision medicine demand. Diaceutics LON:DXRX is entering the second half of 2026 with growing momentum, after a sharp increase in recurring revenue, a stronger order book and positive free cash flow coincided with an expanded partnership with US biopharma group Syndax Pharmaceuticals. The Belfast-based diagnostic intelligence company reported first-half revenue of £17.5m, up 20% year on year and 22% at constant currency. Annual recurring revenue (ARR) was the standout, rising 79% to £29.4m, while the order book increased 38% to £43.7m. The Armchair Trader tipped Diaceutics to its members at 155p on 11 September. The shares closed at 185.86p on Friday. The quality of that growth is also improving. Net revenue retention reached 149%, meaning the existing customer base generated substantially more recurring revenue than a year earlier, while gross ARR churn fell to 6%. Gross margin increased to 85% from 83%, and adjusted EBITDA swung from £57,000 to £1.1m. For shareholders, the move into positive free cash flow is particularly significant. Diaceutics generated £0.7m of free cash flow in the first half, an improvement of £3.1m on the previous year. The company ended June with £8.1m of cash and no debt, leaving it funded to pursue its organic growth strategy. Syndax partnership puts Relay in the spotlight. The latest evidence of Diaceutics' commercial traction came last week, when it announced an expansion of its multi-year Relay partnership with Syndax. The agreement will support the commercialisation of Syndax's precision oncology medicine for acute leukaemia, helping identify eligible patients sooner and supporting more timely access to treatment. The expanded relationship builds on a partnership signed in the fourth quarter of 2025. The financial terms have not been disclosed, but the strategic significance is clearer. Relay brings together Diaceutics' diagnostic regulatory planning, testing intelligence, concordance studies, scientific engagement and physician education into a single commercialisation model. That is important because precision medicines depend on patients being identified through the right diagnostic pathway. Diaceutics aims to use its data and intelligence to show pharmaceutical companies where eligible patients may be missed and help coordinate activity between laboratories, healthcare professionals and commercial teams. Relay is already showing encouraging traction. ARR from existing Relay relationships increased from £2.6m at contract inception to £4.3m at June 30, while the company said new customers were in the final stages of contract negotiations. Bigger market gives Diaceutics room to scale. The broader opportunity could be considerably larger than Diaceutics' historical focus on precision medicine. In September, the company launched its "Precision For All" repositioning, expanding its addressable therapy universe from about 250 precision medicine therapies to more than 1,100 diagnostic-driven therapies. That gives management a much larger potential customer base while allowing it to build on the same underlying diagnostic intelligence infrastructure. Diaceutics already works with 18 of the world's top 20 pharmaceutical companies, supporting 55 customers across 103 therapeutic brands. Its Signal product also saw ARR increase 46% during the first six months of the year and is now used across 55 brands, compared with 36 a year earlier. The company is continuing to invest in its DXRX platform, proprietary data and AI-enabled analytics, while redesigning its commercial and delivery model to support scale and improve operating leverage. Importantly, management has maintained its expectations for 2026. By the end of August, delivered revenue, contracted revenue and the risk-weighted commercial pipeline represented 107% visibility against the £46.7m median analyst consensus revenue estimate for the full year, up from 91% at the end of June. What the Armchair Trader thinks. Diaceutics' latest numbers suggest the business is moving beyond being an interesting healthcare data specialist and towards becoming a more predictable, recurring-revenue software and services company. The 79% increase in ARR is the headline number, but the 149% net revenue retention and falling churn are arguably more important because they show customers are expanding their relationships rather than simply signing once and leaving. The expanded Syndax partnership provides useful evidence that Relay can turn this infrastructure into deeper, multi-year commercial relationships. The risks remain: the company is still loss-making on a statutory basis, its growth depends heavily on winning and expanding pharmaceutical contracts, and the new addressable market will need to translate into actual revenue. Even so, the combination of high gross margins, improving cash generation, no debt and substantial pipeline visibility gives Diaceutics a solid platform. If management can sustain the current level of ARR growth while converting that scale into stronger statutory profitability, shareholders could have a particularly interesting growth story on their hands. Invest with these regulated brokers. Learn with its free 'How to' Guides.

Syndax Pharmaceuticals reported second quarter 2026 total revenue of $73 million, marking a 92% year-over-year increase. Revuforj (revumenib) generated net revenue of $54.7 million, up 91% year-over-year, whilst Niktimvo (axatilimab-csfr) achieved net revenue of $60.3 million, a 67% year-over-year increase, resulting in Syndax collaboration revenue of $18.1 million. The company expanded its pipeline with a novel EGFR inhibitor for non-small cell lung cancer and a next-generation menin inhibitor for myelofibrosis. Topline data from Phase 2 trials of axatilimab in idiopathic pulmonary fibrosis and frontline chronic graft-versus-host disease are expected in the fourth quarter of 2026. For the six months ended 30 June 2026, Syndax reported a net loss of $49.4 million, or $0.55 per share.

Syndax to highlight late-stage programs and unveil new pipeline assets at R&D Event. July 14, 2026 - Expands pipeline with SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor designed to address NSCLC patient populations with significant unmet needs - - SNDX-62122, a next-generation menin inhibitor, selected for development in MF, building on compelling preclinical results observed with revumenib in MF - - SNDX-62122 is the first candidate from the Company's library of internally developed and wholly owned next-generation menin inhibitors that the Company plans to deploy in new areas - - Phase 2 trial of axatilimab in IPF on track for topline data in 4Q26 - - R&D Event featuring three thought leaders and members of Syndax's leadership team to be held today at 8:30 a.m. ET - NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) - Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will highlight its late-stage programs and the next chapter of its R&D strategy, including new pipeline assets, during its R&D Event being held today from 8:30 a.m. to 11:00 a.m. EDT. "Today we are unveiling our new pipeline assets which reflect the continued evolution of our R&D capabilities, including our ability to leverage both external innovation and a library of internally developed next-generation menin inhibitors to expand our portfolio and create new growth opportunities," said Michael A. Metzger, Chief Executive Officer. "With a robust financial foundation, a track record of success, and multiple near-term catalysts, Syndax is positioned to deliver the next breakthroughs for patients and drive long-term value for shareholders." "Syndax has established world-class R&D capabilities and strong partnerships with leading clinicians and scientists around the world to drive innovation and develop transformative new medicines for patients," said Nick Botwood, MBBS, Head of Research & Development and Chief Medical Officer at Syndax. "Today's event will highlight our strategy to expand our leadership in menin and CSF-1R inhibition and build our pipeline with two new differentiated assets supported by compelling preclinical data and mechanistic insights. With both Revuforj and Niktimvo, we demonstrated our ability to efficiently generate clinical data that validates new therapeutic targets, a strength we look forward to showcasing again as we advance the next chapter of our R&D strategy." Guest speakers will include: * Toby M. Maher, MD, PhD, Professor of Clinical Medicine and Director of Interstitial Lung Disease, Keck Medical School of University of Southern California, will present on idiopathic pulmonary fibrosis (IPF) and the potential for axatilimab in IPF. * John D. Crispino, PhD, MBA, Director, Division of Experimental Hematology, St. Jude Children's Research Hospital, will present on the potential for menin inhibition in myelofibrosis (MF). * Michael J. Eck, MD, PhD, Professor, Department of Cancer Biology, Dana-Farber Cancer Institute and Professor, Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School, will present on the development of SNDX-4321 for EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). Highlighted R&D Day Topics SNDX-4321, a novel, mutant-selective, allosteric EGFR inhibitor for NSCLC * SNDX-4321 is an EGFR inhibitor in development for NSCLC patient populations with significant unmet needs, such as those with L858R mutations, CNS metastases, atypical activating mutations, or acquired resistance to current therapies. In contrast to ATP-site directed third and fourth generation EGFR inhibitors, SNDX-4321 is a novel allosteric inhibitor which binds at a pocket adjacent to the ATP site that is only accessible in the presence of L858R and certain other EGFR mutations. The Company expects to submit an investigational new drug (IND) application for SNDX-4321 by the end of 2026 and to initiate a Phase 1 trial in EGFRm NSCLC in 2027. SNDX-4321 is an externally developed molecule that the Company has an exclusive worldwide license to develop and commercialize. During the R&D Event, the Company will highlight the potential advantages of an allosteric approach in EGFRm NSCLC and the supporting preclinical data. SNDX-62122, a candidate from the Company's library of internally developed next-generation menin inhibitors, selected for development in MF * SNDX-62122 is the first candidate from a library of wholly owned next-generation menin inhibitors that the Company intends to advance into new areas. * SNDX-62122 is in development for MF, with submission of an IND and initiation of a Phase 1 trial in MF expected in 2027. During the R&D Event, the Company will highlight recently published revumenib preclinical data showing that menin is a novel dependency in proliferative megakaryocytes, major drivers of MF. The Company expects the development of SNDX-62122 to be informed and de-risked by a Phase 1/2 proof-of-principal trial of revumenib in MF that is expected to initiate in the fourth quarter of 2026 with initial clinical data expected in the second half of 2027. Ongoing late-stage trials of Revuforj(R)(revumenib) and Niktimvo(TM)(axatilimab-csfr) * During the R&D event, the Company will highlight its late-stage revumenib and axatilimab programs in newly diagnosed acute leukemia and chronic GVHD, respectively, as well as the Phase 2 trial of axatilimab in IPF that is expected to readout in the fourth quarter of 2026. During the R&D event, Dr. Toby M. Maher will discuss the unmet patient needs, evolving treatment landscape, and the potential for axatilimab's mechanism in IPF. Syndax will host an R&D Event today, July 14, 2026, from 8:30 a.m. to 11:00 a.m. ET in person and via webcast. The live audio webcast and accompanying slides may be accessed through the Events & Presentations page in the Investors section of the Company's website. Alternatively, the conference call may be accessed through the following link: https://sndx-rdevent-2026.open-exchange.net/. For those unable to join the live webcast, a replay will be available in the Investors section of the Company's website at https://syndax.com/ after the event and will be available for a limited time. About Syndax Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj(R)(revumenib), an FDA-approved menin inhibitor, and Niktimvo(TM)(axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by its commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "predict," "project," "should," "will," "would" or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax's product candidates, the acceptance of Syndax and its partners' products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj's or Niktimvo's commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax's collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. Syndax Contact Sharon Klahre Syndax Pharmaceuticals, Inc. [email protected] Tel 781.684.9827